Polyene macrolides nystatin and amphotericin B are widely used in the treatment of fungal infections. In order to characterize factors affecting polyene activity, we have isolated Saccharomyces cerevisiae mutants showing selective resistance to nystatin and amphotericin B. Characterization of two of these mutants (nystatin-resistant mutant X1/16 and amphotericin B-resistant mutant X3/33) is presented. Genetic analysis revealed that resistance in each of these mutants is caused by a mutation in one gene with a different mode of inheritance. Nystatin resistance in mutant X1/16 is caused by changes in sterol spectrum while amphotericin B resistance in mutant X3/33 is probably related to modification of the cell wall. Our results suggest that, in spite of their structural similarity, nystatin and amphotericin B differ significantly in mechanisms of their antifungal activity.
Introduction
After more than 40 years of use in antifungal therapy, polyene macrolides nystatin and amphotericin B (Figure 1 ) still represent the first line treatment of severe systemic fungal infections and several topical mycoses. The good reputation of nystatin and amphotericin B results from their high efficiency in killing a wide spectrum of pathogenic yeasts and filamentous fungi. However, this efficiency of nystatin and amphotericin B has its reverse consequence in severe side effects (both chronic and acute) even at moderate therapeutic doses. These side effects are related to the similarity of pathogen and host cells, which represents a limiting factor especially in the treatment of systemic mycoses.
Earlier biochemical and biophysical studies (reviewed in [1] ) identified the impairment of membrane barrier function as the most important mechanism of polyene activity. Depending on specific conditions (e.g. drug concentration, aggregation status and membrane composition), polyeneinduced defects may range from small 'pinhole-like' leaks to extensive membrane breakdown. Molecular mechanisms of polyene activity are explained by a model of transmembrane channels proposed by De Kruijff and Demel [2] . These channels composed of alternating polyene and sterol molecules induce leak of intracellular ions and metabolites, leading to ultimate cell death. Although this model has been modified in several aspects (e.g. number of polyene molecules involved and role of phospholipids), it is still in agreement with the majority of experimental data. Since human cholesterol and fungal ergosterol have similar structure, polyenes are able to interact with both host and pathogen membranes. Selective effect of polyenes on fungal cells is explained by their higher affinity for ergosterol-containing fungal membranes or by higher stability of polyene-ergosterol channels. The role of ergosterol in polyene antifungal activity is supported especially by isolation of polyene-resistant mutants showing reduced ergosterol content (see [3] , for a recent review).
Similarity between the membranes of human and fungal membranes leaves only a relatively narrow window of useful therapeutic concentrations. In principle, this range can be extended in two ways. The upper limit can be raised by reducing the side effects, e.g. by use of new polyene formulations (for a review, see [4] ). Therapeutic index of polyenes could be improved also by decreasing the lower limit of effective fungicidal concentrations. This could be achieved by modifying the sensitivity of the target pathogen organism. There are several indications that in vivo sensitivity of pathogenic fungi is affected by factors not directly related to membrane sterols, e.g. by cell wall composition [5, 6] , fatty acid content [7] or antioxidative defence [8, 9] . One of the approaches that could identify cellular processes related to polyene activity is genome-wide analysis of gene expression induced by polyene treatment. Two such studies have been performed in Saccharomyces cerevisiae so far. The study of Agarwal et al. [10] was aimed at transcription profiling of cells treated by four antimycotics with different modes of action, ketoconazole, amphotericin B, caspofungin and 5-fluorocytosine. In this study, 265 genes responsive to amphotericin treatment were identified (185 with increased expression and 80 with reduced expression) including a relatively large set of 86 genes with unknown function. Comparison of the four sets of antimycotic-responsive genes revealed that genes involved in stress response, phosphate metabolism, membrane transport and cell-wall maintenance represented the genes specific for amphotericin B. The other study of Zhang et al. [11] compared genome response to treatment with nystatin and amhotericin B. Sets of genes responding to these two polyenes showed a significant overlap (75% of genes responding to nystatin were responding also to amphotericin B). Moreover, none of the genes induced by one substance was repressed by the other. These results suggest that nystatin and amphotericin B have essentially identical mechanisms of action. Although both studies brought different conclusions in some aspects, both identified membrane transport and cell stress response as the major responses to polyene treatment. Whole genome microarray studies have thus confirmed that plasma-membrane permeabilization is the principal mechanism of polyene action. However, the large set of responsive genes with unknown function leaves open the possibility of the involvement of other unidentified cellular processes in fungal response to polyene antimycotics. In our study, we have focused on such alternative processes modulating polyene sensitivity by selection for mutants selectively resistant to either nystatin or amphotericin B. By isolation of mutants selective to only one of these structurally similar polyenes, we expected to eliminate the most common type of polyene resistance caused by quantitative and qualitative changes in sterol content.
Materials and methods
All experiments described here were performed on S. cerevisiae strain W303-1B (genotype MATα ade2-1 his3-11,15  leu2-3,112 trp1-1 ura3-1 can 1-100 ) and mutants derived from this strain by EMS (ethane methyl sulphonate) mutagenesis. Susceptibility testing was performed by drop tests on YPD (yeast extract/peptone/dextrose) agar plates or in complete YPD liquid medium as described in [17] . Cellular lipids were extracted by the chloroform/methanol method of Bligh and Dyer [18] and saponified by methanolic KOH prior to HPLC analysis. Non-saponifiable lipids were separated by HPLC on Phillips HPLC system with UV detector at 210 nm on Spherics C18 column (length 250 mm, diameter 4.6 mm and particle size 5 µm) with methanol/water (98:2) as the mobile phase at a flow rate of 1 ml/min. Spectrofluorimetric permeabilization assay was performed in non-growing yeast cells on spectrofluorimeter Perkin Elmer 50B (Time Drive mode, λ excitation = 520 nm and λ emission = 610 nm) as described previously [17] .
Results and discussion
After EMS mutagenesis of S. cerevisiae strain W303-1B, we isolated two mutant clones each showing moderate resistance (2.5-fold increase in minimal inhibitory concentration in liquid complete medium) against either nystatin or amphotericin B. This resistance was selective as both mutants retained parental sensitivity to the other polyene. Tetrad analysis of these two mutants revealed that each mutation occurred in a single gene. Specific character of each mutation was indicated also by a different mode of inheritance in genetic crosses (recessive for Nys R and dominant for AmB R ). We performed a detailed phenotypic analysis of these mutant clones including growth on various carbon sources and at different temperatures, sensitivity to other unrelated inhibitors, sensitivity to external stress (cations, ethanol, hyperosmotic medium and oxidative stress) and cell wall properties. This analysis revealed that the nystatin-resistant mutant X1/16 was sensitive to several of the tested conditions. It was hypersensitive to various metabolic inhibitors including the sterol synthesis inhibitors terbinafin and itraconazole and it did not grow at elevated ethanol concentrations and at low temperatures. On the other hand, the amphotericin B-resistant mutant X3/33 performed in all analyses indistinguishably from the parental strain except for its higher resistance to the cell wall-digesting enzyme helicase and slightly elevated content of cell wall glucans.
Effect of nystatin and amphotericin B was also tested in vitro in a permeabilization assay using the fluorescent vital dye propidium iodide (Figure 2) . Treatment of cells with nystatin resulted in responses expected from the growth studiesidentical sensitivities of parental and amphotericin B-resistant strains and much slower kinetics of permeabilization in the nystatin-resistant strain (Figure 2A) . A surprising absence of response was observed in amphotericin B-treated cells; propidium iodide staining was not observed in any of the tested strains even at a high concentration of 40 µg/ml (Figure 2B) . This was in contrast with the estimation of viability in plating tests when treatment with 4-fold lower concentration of amphotericin B under identical conditions resulted in significant killing, particularly of parental and nystatin-resistant cells. Although staining with propidium iodide may indicate more extensive membrane defects than the primary polyeneergosterol channels, striking difference in this assay indicates divergent action of nystatin and amphotericin B on yeast plasma membrane. Several phenotypic characteristics of the nystatin-resistant mutant X1/16 indicated defective plasma membrane in this mutant. We therefore analysed lipid composition of parental strain and both mutant clones. HPLC analysis of non-saponifiable lipids (Figure 3 ) revealed dramatic changes in sterol spectrum in the nystatin-resistant mutant, particularly strong reduction of ergosterol and accumulation of a precursor identified by GC-MS as ergosta-7,22-dien-3-ol. No changes in sterol spectrum were observed in the amphotericin B-resistant mutant X3/33.
Summarizing our results, polyene resistance in two isolated mutants has been tracked down to defects in the ergosterol biosynthesis pathway in the nystatin-resistant mutant X1/16 and to changes in cell wall in the amphotericin-resistant mutant X3/33. Although changes in cell wall structure and/or composition need to be verified further, amphotericinspecific interactions with cell wall indicated in our study would be surprising with respect to structural similarity of nystatin and amphotericin B (Figure 1 ). Accumulation Lipid extracts were hydrolysed in methanolic KOH and separated by HPLC as described in the Materials and methods section. Individual peaks were identified by independent GC-MS analysis. Peak 1, ergosterol; peak 2, ergosta-7,22-dien-3-ol.
of ergosta-7,22-dien-3-ol observed in X1/16 mutant is characteristic for erg3 mutants defective in sterol C-5 desaturase [12] . This defect seems to be present also in our mutant since transformation of X1/16 mutant with wild-type gene library identified a complementing fragment containing the ERG3 gene. The effect of changes in sterol composition on the phenotype of X1/16 mutant is interesting in various aspects. Particularly remarkable is its selective resistance to nystatin and sensitivity to amphotericin B. In fact, we are not aware of any report on such differential sensitivity to these polyenes in mutants with altered sterol biosynthesis. The other interesting characteristic of the mutant X1/16 is its hypersensitivity to azoles. Azole resistance seems to be typical for erg3 mutants in S. cerevisiae [12] . Moreover, erg3 mutants in several yeast species show cross-resistance to azoles and amphotericin B [13] [14] [15] [16] . The specific sensitivity pattern (resistance to nystatin, wild-type sensitivity to amphotericin B and increased sensitivity to itraconazole) seems to be a unique feature of our X1/16 mutant. Together with the lack of permeabilization to propidium iodide in all cell types (parental, nystatin-resistant and amphotericin Bresistant) even at high amphotericin B concentrations, these results indicate significant differences in the action of the structurally very similar polyene antimycotics nystatin and amphotericin B in yeast.
